A rare case of a drug-induced vasculitis by hydralazine

Young Min Cho, MD; Alex Adams, DO; Ernest Han, MD, and Dimpoo Patel, MD

Learning and objective:

- Recognize clinical presentation of drug-induced vasculitis (DIV) in order to provide the best treatment
- Understand the serology result of DIV
- Recognize the unusual serology presentation on DIV

Introduction:

Hydralazine-induced vasculitis is a rare disease that can manifest with renal and pulmonary involvement. Drug-induced, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (DIV) is a very aggressive and severe vasculitis that can lead to renal failure. Seven cases of hydralazine-induced vasculitis in the literature all had renal involvement (pauci-immune glomerulonephritis) (1) Fig.1. Case series have shown that twelve patients who were diagnosed with DIV by hydralazine, nine had C3 abnormalities, five for C4, twelve with ANA, eleven anti-DNA, eleven with anti-histone, and eleven with myeloperoxidase (MPO) (2).

Clinical case:

34-year-old Caucasian male with a PMH of hypertension (HTN), chronic kidney disease (CKD) stage 3 and mineral-bone disorder (MBD), who was admitted to the hospital in 2017 for dyspnea with a pleural effusion and low-grade fever (37.2°C). On his basic work up, patient presented with an elevated creatinine level. ROS: no chills and dysuria Laboratory:

- Creatinine: 3.5 mg/dL, (baseline 2.15 mg/dL).
- Urinalysis: 5 RBC and 1+ proteinuria, and protein creatinine ratio of 0.7
- Coagulation profile: PT 50.6 (22.5-35.1s), PT 15.1 (11.7-14.5 s), INR 1.17 (0.87-1.17)
- Thoracentesis: shows exudative pleural effusion with a negative culture.

Due to the presence of microscopic hematuria and proteinuria (6 g/day) in the setting of acute kidney injury at a relatively young age, subsequent serology was sent for analysis.

Serology on Fig. 2(b)

The biopsy was postponed because of an active PTT of 56 with the subsequent mixing test showing prolongation due to serum antiphospholipid antibodies.

Treatment: Discontinued hydralazine and Losartan. Began empiric daily prednisone 60mg and cyclophosphamide 150mg.

Biopsy 1 month after hospitalization: light/electron microscopy and immunofluorescence revealing 1-2+ granular global mesangial positivity for IgM. Glomeruli were negative for IgA, IgG, C1q, albumin, fibrinogen, and kappA. The findings were consistent with diagnosis of Focal crescentic glomerulonephritis, pauci-immune type (ANCA-associated/clinal).

After 3 months of prednisone and cyclophosphamide renal function had improved with serum creatinine levels trending back towards 2 mg/dL. Immunosuppressant therapy was subsequently tapered down over the next 5 months. Therapy was discontinued at 6 months with full return of renal function.

Discussion:

- Hydralazine-induced vasculitis usually presents as ANA positive, with hypocomplementemia. This patient presented with MPO and PR3 antibodies together plus absence of ANA and hypocomplementemia which is very unusual (4). We questioned whether the hydralazine was the only factor that triggered the ANCA vasculitis or was it another non-classical DIV presentation?
- The symptomatic presentation and the response of discontinuing the medication and treatment with immunosuppressive helped confirm the diagnosis.
- The patient had a bleeding risk factor due to the presence of antiphospholipid antibodies and that was very challenging because it delayed to obtain the biopsy. We started with empiric treatment because of progressive symptoms in the patient. Biopsy verified pauci-immune type (ANCA-associated) vasculitis.

Fig.1. Light microscopy: (a) glomeruli with cellular crescents; (b) IF: glomeruli with trace IgM membranous deposits; (c) glomeruli with trace IgG membranous deposits; (d) EM: GBM thickening FPE effacement, and absent deposits on capillary and mesangium (3).

Fig.2. (a) AP X-ray and pleural analysis: Bilateral pleural effusions. right greater than left. Bilateral lung base atelectasis.

Fig.2. (b) Antigens and antibodies (Ab) profile: (a) Antibodies, Value, and Reference:

<table>
<thead>
<tr>
<th>Antibodies</th>
<th>Value</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myeloperoxidase antibody (Ab)</td>
<td>126 AU/mL</td>
<td>0 to 19 AU/mL</td>
</tr>
<tr>
<td>Proteinase-3</td>
<td>42 AU/Ml</td>
<td>0 to 19 AU/Ml</td>
</tr>
<tr>
<td>Anti-Neutrophil Cytoplasmic Ab, IgG</td>
<td>1:320</td>
<td>Reference range: &lt;1:20</td>
</tr>
<tr>
<td>Antinuclear antibodies</td>
<td>negative</td>
<td></td>
</tr>
<tr>
<td>Anti–glomerular basement membrane Ab</td>
<td>&lt;0.2 U</td>
<td>&lt;1.0 U</td>
</tr>
<tr>
<td>Histone Ab</td>
<td>2.3 U moderate positive</td>
<td>&lt;5 U</td>
</tr>
<tr>
<td>C3 complement</td>
<td>135 mg/dL</td>
<td>90.180 mg/dL</td>
</tr>
<tr>
<td>C4 complement</td>
<td>27 mg/dL</td>
<td>10-40 mg/dL</td>
</tr>
</tbody>
</table>

Reference: